RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 129 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47 | +2.2% | 6,184 | 0.0% | 0.00% | – |
| Q2 2023 | $46 | +12.2% | 6,184 | +0.6% | 0.00% | – |
| Q1 2023 | $41 | +1950.0% | 6,145 | +1888.7% | 0.00% | – |
| Q4 2022 | $2 | -100.0% | 309 | -96.6% | 0.00% | -100.0% |
| Q3 2022 | $96,000 | +159.5% | 8,990 | +99.3% | 0.00% | – |
| Q2 2022 | $37,000 | -51.9% | 4,510 | 0.0% | 0.00% | -100.0% |
| Q4 2021 | $77,000 | +7600.0% | 4,510 | +14933.3% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
| Q4 2020 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
| Q1 2020 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
| Q4 2019 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
| Q3 2019 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
| Q2 2019 | $1,000 | 0.0% | 30 | 0.0% | 0.00% | – |
| Q1 2019 | $1,000 | – | 30 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Obvious Management Services, L.L.C. | 5,977,631 | $42,800,000 | 100.00% |
| Two Sigma Ventures, LP | 1,806,800 | $12,937,000 | 74.73% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $28,290,000 | 31.54% |
| MV Management XI, L.L.C. | 1,971,908 | $14,119,000 | 9.80% |
| Data Collective IV GP, LLC | 5,941,120 | $42,538,000 | 9.03% |
| ArchPoint Investors | 1,267,430 | $9,075,000 | 3.13% |
| MIC Capital Management UK LLP | 1,388,889 | $9,944,000 | 1.94% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $10,806,000 | 1.09% |
| Samsara BioCapital, LLC | 539,236 | $3,861,000 | 0.97% |
| Pinz Capital Management, LP | 142,168 | $1,018,000 | 0.64% |